ID   HuH-6 Clone 5
AC   CVCL_1296
SY   HuH-6 clone-5; Huh-6 clone 5; HUH-6 Clone 5; HUH-6-clone 5; HUH-6-clone5; HUH6CLONE5; HuH-6 cl-5; HuH-6-cl5; HUH6-Cl-5; HuH-6 cl5; HuH6-Cl5; HUH6 Cl5; HUH6 CL5; Huh6cl5; HuH6-C15; Huh6-c15; HUH6 C15; Huh6c15; JTC38; JTC-38; Japanese Tissue Culture-38
DR   ArrayExpress; E-MTAB-783
DR   BioSample; SAMN03471623
DR   cancercelllines; CVCL_1296
DR   Cell_Model_Passport; SIDM01257
DR   ChEMBL-Cells; CHEMBL3308701
DR   Cosmic; 907070
DR   Cosmic-CLP; 907070
DR   DepMap; ACH-002395
DR   GDSC; 907070
DR   GEO; GSM2551569
DR   IARC_TP53; 21384
DR   JCRB; JCRB0401
DR   LIMORE; HuH6
DR   PharmacoDB; HUH6clone5_639_2019
DR   Wikidata; Q54896849
RX   PubMed=57894;
RX   PubMed=6161524;
RX   PubMed=6290537;
RX   PubMed=6301464;
RX   PubMed=8835345;
RX   PubMed=9290701;
RX   PubMed=20164919;
RX   PubMed=30894373;
RX   PubMed=31378681;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: Liver Cancer Model Repository (LIMORE).
CC   Population: Japanese.
CC   Doubling time: 25.57 hours (PubMed=31378681); 35 hours (Note=Lot 05262008), 38-55 hours (Note=Lot 12142012), ~37 hours (Note=Lot 07222016) (JCRB=JCRB0401).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Val (c.101G>T); ClinVar=VCV000017582; Zygosity=Heterozygous (PubMed=31378681; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala159Asp (c.476C>A); ClinVar=VCV001026335; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn239Asp (c.715A>G); ClinVar=VCV000234036; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Genome sequenced.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=1.77%; Native American=1.36%; East Asian, North=76.85%; East Asian, South=16.52%; South Asian=0%; European, North=0%; European, South=3.49% (PubMed=30894373).
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
ST   Source(s): Cosmic-CLP; JCRB; PubMed=31378681
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 8,12
ST   D16S539: 10,11
ST   D5S818: 8,11
ST   D7S820: 11,12
ST   TH01: 7,8
ST   TPOX: 8
ST   vWA: 14,17
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4381 ! HuH-6
SX   Male
AG   1Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 34
//
RX   PubMed=57894;
RA   Doi I.;
RT   "Establishment of a cell line and its clonal sublines from a patient
RT   with hepatoblastoma.";
RL   Gann 67:1-10(1976).
//
RX   PubMed=6161524; DOI=10.18926/AMO/30534;
RA   Miyamoto K., Taketa K., Yabe T., Miyano K., Sato J.;
RT   "Chromosome analysis in a human hepato-blastoma cell line producing
RT   alpha-fetoprotein.";
RL   Acta Med. Okayama 34:127-130(1980).
//
RX   PubMed=6290537; DOI=10.1172/JCI110701;
RA   Amuro Y., Tanaka M., Higashino K., Hayashi E., Endo T., Kishimoto S.,
RA   Nakabayashi H., Sato J.;
RT   "Bile acid synthesis by long-term cultured cell line established from
RT   human hepatoblastoma.";
RL   J. Clin. Invest. 70:1128-1130(1982).
//
RX   PubMed=6301464; DOI=10.1016/0006-291X(83)91037-9;
RA   Tanaka M., Kawamura K., Fang M.-Q., Higashino K., Kishimoto S.,
RA   Nakabayashi H., Sato J.;
RT   "Production of fibronectin by HUH6 C15 cell line established from a
RT   human hepatoblastoma.";
RL   Biochem. Biophys. Res. Commun. 110:837-841(1983).
//
RX   PubMed=8835345; DOI=10.1002/(SICI)1096-9071(199602)48:2<133::AID-JMV3>3.0.CO;2-A;
RA   Tsuboi S., Nagamori S., Miyazaki M., Mihara K., Fukaya K.-i., Teruya K.,
RA   Kosaka T., Tsuji T., Namba M.;
RT   "Persistence of hepatitis C virus RNA in established human
RT   hepatocellular carcinoma cell lines.";
RL   J. Med. Virol. 48:133-140(1996).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31378681; DOI=10.1016/j.ccell.2019.07.001;
RA   Qiu Z.-X., Li H., Zhang Z.-T., Zhu Z.-F., He S., Wang X.-J.,
RA   Wang P.-C., Qin J.-J., Zhuang L.-P., Wang W., Xie F.-B., Gu Y.,
RA   Zou K.-K., Li C., Li C., Wang C.-H., Cen J., Chen X.-T., Shu Y.-J.,
RA   Zhang Z., Sun L.-L., Min L.-H., Fu Y., Huang X.-W., Lv H., Zhou H.,
RA   Ji Y., Zhang Z.-G., Meng Z.-Q., Shi X.-L., Zhang H.-B., Li Y.-X.,
RA   Hui L.-J.;
RT   "A pharmacogenomic landscape in human liver cancers.";
RL   Cancer Cell 36:179-193.e11(2019).
//